Drug Trial Radar · NCT01394263
Study of Histrelin Subdermal Implant in Patients With Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jan 2, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
59
Actual
Start
May 2000
Primary completion
Dec 2001
Study completion Dec 2003
Sponsor
- Lead sponsor
- Endo USA Inc., a Keenova Therapeutics CompanyIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial was an open-label, multi-national, randomized, parallel treatment, active-control multicenter study in adult males with documented metastatic prostate cancer disease who were judged to be candidates for hormone therapy.
Conditions
- Prostate Cancer
- Adenocarcinoma of the Prostate
Interventions
Histrelin hydrogel implantDrug
50 mg histrelin acetate in hyrogel implant
Zoladex goserelin implantDrug
goserelin implant injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Suppression of testosterone via the percent of patients whose testosterone was at or below chemical castration levels (<=50 n/dL) through 52 weeks of treatment.Time frame: 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.